BioMarin Pharmaceutical Inc. (FRA:BM8)
Germany · Delayed Price · Currency is EUR | Market Cap | 10.79B +22.5% |
| Revenue (ttm) | 2.98B +11.2% |
| Net Income | 63.87M -88.9% |
| EPS | 0.33 -88.9% |
| Shares Out | n/a |
| PE Ratio | 168.97 |
| Forward PE | 10.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 56.70 |
| Previous Close | 56.36 |
| Day's Range | 56.70 - 56.70 |
| 52-Week Range | 42.62 - 60.74 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]
Financial Performance
In 2025, BioMarin Pharmaceutical's revenue was $3.22 billion, an increase of 12.87% compared to the previous year's $2.85 billion. Earnings were $348.90 million, a decrease of -18.26%.
Financial numbers in USD Financial StatementsNews
BioMarin price target lowered to $97 from $98 at BMO Capital
BMO Capital lowered the firm’s price target on BioMarin (BMRN) to $97 from $98 and keeps an Outperform rating on the shares after the company discontinued development of Voxzogo in…
BioMarin to discontinue development of Voxzogo for children with Noonan syndrome
In a regulatory filing, BioMarin (BMRN) Pharmaceutical disclosed its decision to discontinue development of Voxzogo for children with Noonan syndrome. “BioMarin made this decision after assessing a nu...
BioMarin Pharmaceutical Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Integration of recent acquisitions is driving new growth, with Amicus and Alesta expanding the pipeline and financial strength. Key products like VOXZOGO, GALAFOLD, and POMBILITI + OPFOLDA are set for significant growth, while operational synergies and deleveraging targets are on track.
BioMarin names Robert Plenge, M.D., Ph.D., to board of directors
BioMarin Pharmaceutical (BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company’s Board of Directors, effective September 10. Dr. Plenge is Executive Vice President,...
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D.
BioMarin Pharmaceutical Transcript: Citigroup’s Biopharma Back to School Summit 2026
Key priorities include expanding blockbuster therapies and leveraging recent acquisitions for growth. Pipeline advances feature VOXZOGO's strong performance, new indications, and innovative assets like BMN 333 and ALE-01. AI tools are streamlining R&D and patient identification.
BioMarin Pharmaceutical Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Significant portfolio expansion and strong financial growth were highlighted, with new assets from the Amicus acquisition expected to drive substantial revenue and EPS accretion. VOXZOGO remains a key growth driver, while promising pipeline developments and global expansion underpin long-term strategy.
BioMarin Pharmaceutical Transcript: Wells Fargo 21st Annual Healthcare Conference
Metabolic and skeletal franchises are driving robust growth, with VOXZOGO and Amicus products expanding globally. The pipeline is advancing with promising data in hypochondroplasia, new deals, and upcoming readouts for BMN 333, BMN 351, and FSGS. Strategic settlements and international expansion underpin future revenue.
BioMarin reports new data from Phase 3 CANOPY-HCH-3 study
BioMarin (BMRN) Pharmaceutical announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO, or vosoritide, in children with hypochondroplasia were published in New England Journal of Med...
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual ...
BioMarin to Participate in Upcoming Investor Conferences
Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST Citi's 2026 Biopharma Back to School Conference, Septem...
BioMarin completes agreement to acquire Alesta Therapeutics
BioMarin Pharmaceutical (BMRN) said that it completed the previously announced agreement to acquire Alesta Therapeutics. The acquisition will strengthen BioMarin’s skeletal conditions portfolio, addin...
BioMarin Announces Close of the Alesta Therapeutics Acquisition
Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today...
BioMarin price target raised to $86 from $85 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on BioMarin (BMRN) to $86 from $85 and keeps an Overweight rating on the shares after the company reached a settlement with Ascendis…
BioMarin price target raised to $90 from $88 at Piper Sandler
Piper Sandler analyst Allison M. Bratzel raised the firm’s price target on BioMarin (BMRN) to $90 from $88 and keeps an Overweight rating on the shares on news of a…
H.C. Wainwright trims Ascendis target, says litigation overhang removed
H.C. Wainwright lowered the firm’s price target on Ascendis Pharma (ASND) to $344 from $345 and keeps a Buy rating on the shares. The Yuviwel royalty settlement with BioMarin (BMRN)…
BioMarin price target raised to $105 from $104 at Jefferies
Jefferies analyst Akash Tewari raised the firm’s price target on BioMarin (BMRN) to $105 from $104 and keeps a Buy rating on the shares. The firm notes the company announced…
BioMarin price target raised to $60 from $59 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BioMarin (BMRN) to $60 from $59 and keeps a Neutral rating on the shares after Ascendis Pharma (ASND) agreed to pay the…
Ascendis Pharma Stock (ASND) Soars 7% on a Settlement with BioMarin Pharmaceutical (BMRN)
Ascendis Pharma stock rallied 7% on Monday after the company reached a global settlement and license deal with BioMarin Pharmaceutical.
BioMarin price target raised to $109 from $105 at Raymond James
Raymond James raised the firm’s price target on BioMarin (BMRN) to $109 from $105 and keeps an Outperform rating on the shares following the announcement of a settlement with Ascendis…
BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma
BioMarin (BMRN) announced that it has entered into binding terms with Ascendis Pharma (ASND), resolving the patent and ancillary disputes pending globally, including before the U.S. International Trad...
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced th...
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment
BioMarin will acquire Alesta Therapeutics for $275 million upfront, and up to an additional $215 million based on milestones. Alesta Therapeutic's lead drug is a potential treatment for hypophosphatas...
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones Alesta to spin out all non-ALE1 assets to a new entity and Alesta employees to ...
BioMarin Pharmaceutical Transcript: Canaccord Genuity's 46th Annual Growth Conference
A rare disease-focused company reported strong Q2 growth, raised full-year guidance, and accelerated its de-leveraging timeline following the Amicus acquisition. Key growth drivers include global expansion of new assets, VOXZOGO's performance, and a robust pipeline, with continued focus on strategic business development.